NASDAQ:GNFT

Genfit Competitors

$4.31
-0.02 (-0.46 %)
(As of 04/20/2021 11:35 AM ET)
Add
Compare
Today's Range
$4.31
Now: $4.31
$4.34
50-Day Range
$4.31
MA: $4.72
$5.10
52-Week Range
$3.63
Now: $4.31
$22.48
Volume717 shs
Average Volume225,988 shs
Market Capitalization$180.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.33

Competitors

Genfit (NASDAQ:GNFT) Vs. INBX, DBVT, HARP, ATHA, VXRT, and MGTX

Should you be buying GNFT stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Genfit, including Inhibrx (INBX), DBV Technologies (DBVT), Harpoon Therapeutics (HARP), Athira Pharma (ATHA), Vaxart (VXRT), and MeiraGTx (MGTX).

Inhibrx (NASDAQ:INBX) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares Inhibrx and Genfit's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InhibrxN/AN/AN/A
GenfitN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Inhibrx and Genfit, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inhibrx00403.00
Genfit32502.20

Inhibrx currently has a consensus price target of $34.6667, suggesting a potential upside of 98.89%. Genfit has a consensus price target of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher possible upside, analysts clearly believe Genfit is more favorable than Inhibrx.

Institutional & Insider Ownership

36.6% of Inhibrx shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Inhibrx and Genfit's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InhibrxN/AN/AN/AN/AN/A
Genfit$45.88 million3.94$-72,960,000.00($1.97)-2.19

Inhibrx has higher earnings, but lower revenue than Genfit.

Summary

Genfit beats Inhibrx on 3 of the 5 factors compared between the two stocks.

DBV Technologies (NASDAQ:DBVT) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares DBV Technologies and Genfit's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DBV TechnologiesN/AN/AN/A
GenfitN/AN/AN/A

Risk & Volatility

DBV Technologies has a beta of 2.91, suggesting that its stock price is 191% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for DBV Technologies and Genfit, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DBV Technologies23402.22
Genfit32502.20

DBV Technologies currently has a consensus price target of $7.25, suggesting a potential upside of 22.88%. Genfit has a consensus price target of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher possible upside, analysts clearly believe Genfit is more favorable than DBV Technologies.

Institutional & Insider Ownership

32.5% of DBV Technologies shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. 15.3% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares DBV Technologies and Genfit's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DBV Technologies$14.75 million43.95$-172,020,000.00($2.33)-2.53
Genfit$45.88 million3.94$-72,960,000.00($1.97)-2.19

Genfit has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Genfit, indicating that it is currently the more affordable of the two stocks.

Summary

Genfit beats DBV Technologies on 6 of the 11 factors compared between the two stocks.

Harpoon Therapeutics (NASDAQ:HARP) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares Harpoon Therapeutics and Genfit's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harpoon Therapeutics-434.74%-68.32%-29.45%
GenfitN/AN/AN/A

Risk & Volatility

Harpoon Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Harpoon Therapeutics and Genfit, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harpoon Therapeutics00803.00
Genfit32502.20

Harpoon Therapeutics currently has a consensus price target of $31.75, suggesting a potential upside of 71.25%. Genfit has a consensus price target of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher possible upside, analysts clearly believe Genfit is more favorable than Harpoon Therapeutics.

Institutional & Insider Ownership

79.0% of Harpoon Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. 34.9% of Harpoon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Harpoon Therapeutics and Genfit's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harpoon Therapeutics$5.78 million104.41$-55,570,000.00($2.55)-7.30
Genfit$45.88 million3.94$-72,960,000.00($1.97)-2.19

Harpoon Therapeutics has higher earnings, but lower revenue than Genfit. Harpoon Therapeutics is trading at a lower price-to-earnings ratio than Genfit, indicating that it is currently the more affordable of the two stocks.

Summary

Genfit beats Harpoon Therapeutics on 8 of the 14 factors compared between the two stocks.

Athira Pharma (NASDAQ:ATHA) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares Athira Pharma and Genfit's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Athira PharmaN/AN/AN/A
GenfitN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Athira Pharma and Genfit, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Athira Pharma00403.00
Genfit32502.20

Athira Pharma currently has a consensus price target of $42.50, suggesting a potential upside of 151.78%. Genfit has a consensus price target of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher possible upside, analysts clearly believe Genfit is more favorable than Athira Pharma.

Institutional & Insider Ownership

66.7% of Athira Pharma shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Athira Pharma and Genfit's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athira PharmaN/AN/A$-5,160,000.00N/AN/A
Genfit$45.88 million3.94$-72,960,000.00($1.97)-2.19

Athira Pharma has higher earnings, but lower revenue than Genfit.

Vaxart (NASDAQ:VXRT) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Risk & Volatility

Vaxart has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Valuation and Earnings

This table compares Vaxart and Genfit's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaxart$9.86 million59.24$-18,650,000.00($0.86)-5.77
Genfit$45.88 million3.94$-72,960,000.00($1.97)-2.19

Vaxart has higher earnings, but lower revenue than Genfit. Vaxart is trading at a lower price-to-earnings ratio than Genfit, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

17.9% of Vaxart shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. 7.3% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Vaxart and Genfit's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vaxart-281.50%-84.90%-44.67%
GenfitN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Vaxart and Genfit, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaxart00203.00
Genfit32502.20

Vaxart currently has a consensus price target of $15.00, suggesting a potential upside of 204.88%. Genfit has a consensus price target of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher possible upside, analysts clearly believe Genfit is more favorable than Vaxart.

Summary

Genfit beats Vaxart on 8 of the 14 factors compared between the two stocks.

MeiraGTx (NASDAQ:MGTX) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

MeiraGTx has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Valuation & Earnings

This table compares MeiraGTx and Genfit's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MeiraGTx$13.29 million44.96$-54,750,000.00($1.65)-8.18
Genfit$45.88 million3.94$-72,960,000.00($1.97)-2.19

MeiraGTx has higher earnings, but lower revenue than Genfit. MeiraGTx is trading at a lower price-to-earnings ratio than Genfit, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.4% of MeiraGTx shares are held by institutional investors. Comparatively, 0.4% of Genfit shares are held by institutional investors. 16.5% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares MeiraGTx and Genfit's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MeiraGTx-283.20%-29.14%-17.49%
GenfitN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for MeiraGTx and Genfit, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MeiraGTx00403.00
Genfit32502.20

MeiraGTx currently has a consensus target price of $33.00, suggesting a potential upside of 148.68%. Genfit has a consensus target price of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher possible upside, analysts plainly believe Genfit is more favorable than MeiraGTx.

Summary

Genfit beats MeiraGTx on 7 of the 13 factors compared between the two stocks.


Genfit Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Inhibrx logo
INBX
Inhibrx
1.6$17.71-4.3%$697.58 millionN/A0.00Decrease in Short Interest
DBV Technologies logo
DBVT
DBV Technologies
1.0$5.90-1.4%$657.04 million$14.75 million-2.53Increase in Short Interest
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$18.62-2.9%$621.00 million$5.78 million-8.74Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.1$16.88-1.4%$618.05 millionN/A0.00
Vaxart logo
VXRT
Vaxart
1.3$4.96-3.0%$601.79 million$9.86 million-8.41
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.50-1.3%$590.04 million$13.29 million-9.57News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$27.27-2.1%$570.80 millionN/A0.00
Compugen logo
CGEN
Compugen
1.4$8.13-2.0%$567.20 million$17.80 million-21.97News Coverage
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.50-0.9%$532.89 millionN/A-1.24
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$4.84-1.4%$524.77 millionN/A-2.35
Agenus logo
AGEN
Agenus
1.6$2.59-1.2%$523.99 million$150.05 million-2.38
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$19.22-3.6%$515.87 millionN/A-5.54
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.46-3.9%$464.56 million$22.24 million-4.21
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$4.83-5.0%$450.42 millionN/A-7.55
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$12.25-1.4%$439.22 millionN/A0.00
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$8.65-1.5%$429.80 million$4.36 million-3.02
AVROBIO logo
AVRO
AVROBIO
1.7$10.41-1.4%$427.04 millionN/A-3.15Analyst Downgrade
News Coverage
Opthea logo
OPT
Opthea
1.5$8.96-1.6%$389.38 millionN/A0.00
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$8.73-2.5%$386.30 million$147.87 million-2.90
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$8.62-0.7%$363.22 millionN/A0.00
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$12.02-4.1%$348.65 millionN/A0.00Gap Up
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.13-2.2%$333.34 million$96.12 million-12.15News Coverage
Gap Up
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.84-0.5%$317.70 million$8.15 million-1.47Increase in Short Interest
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.21-1.8%$302.67 million$250,000.00-2.93
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.3$5.21-1.3%$276.39 million$2.91 million-1.82News Coverage
Surface Oncology logo
SURF
Surface Oncology
1.4$6.37-3.0%$273.74 million$15.36 million-9.65
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.06-0.4%$272.23 millionN/A-3.32
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$10.82-0.6%$258.68 millionN/A-7.90
Codiak BioSciences logo
CDAK
Codiak BioSciences
2.0$11.66-0.8%$258.43 millionN/A0.00
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.63-4.3%$237.66 million$4.13 million-3.62
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.50-9.3%$198.89 million$29.35 million-1.74
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$5.51-2.4%$180.63 millionN/A-3.44News Coverage
Gamida Cell logo
GMDA
Gamida Cell
1.4$7.34-1.0%$176.08 millionN/A-5.13News Coverage
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$14.71-4.0%$171.80 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
INmune Bio logo
INMB
INmune Bio
1.5$11.10-2.4%$169.79 millionN/A-11.44
Axcella Health logo
AXLA
Axcella Health
1.6$4.21-6.9%$169.61 millionN/A-1.96
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$4.54-1.5%$168.31 million$104.39 million-2.77Analyst Report
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.01-4.2%$162.78 millionN/A-7.33Analyst Report
News Coverage
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.68-3.3%$162.46 million$2.45 million-1.73
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.05-2.8%$161.67 millionN/A-2.83
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$7.18-3.8%$152.12 millionN/A-1.83News Coverage
Champions Oncology logo
CSBR
Champions Oncology
1.8$11.00-0.3%$147.69 million$32.12 million-84.62
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.4$10.50-0.5%$138.29 million$2.33 million0.00News Coverage
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$5.95-4.5%$134.46 millionN/A0.00News Coverage
Dyadic International logo
DYAI
Dyadic International
1.3$4.80-1.0%$133.64 million$1.68 million-14.12
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$12.98-0.6%$132.73 millionN/A0.00
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.10-0.0%$130.13 million$20,000.000.00
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$7.12-6.9%$117.80 million$3 million-2.29Gap Up
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.16-2.8%$112.39 millionN/A-1.49
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$3.96-3.0%$111.91 million$23.05 million-1.76
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.